FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to a monoclonal antibody against IL-17A. Also disclosed is a vector expressing said antibody, a pharmaceutical composition comprising said antibody. Disclosed is the use of said antibody, a method of treating a disease or disorder with said antibody.
EFFECT: invention has the ability to effectively treat diseases associated with IL-17A.
22 cl, 5 ex, 11 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| ANTIBODY AGAINST LAG-3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR PHARMACEUTICAL APPLICATION | 2017 |
|
RU2757813C2 |
| SCLEROSTIN ANTIBODY, ITS ANTIGEN-BINDING FRAGMENT AND MEDICAL APPLICATION | 2016 |
|
RU2716101C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| HETERODIMERIC BISPECIFIC ANTIBODY AGAINST TNFα/AGAINST IL-17A, SIMILAR BY STRUCTURE TO NATURAL ANTIBODY, AND ITS PRODUCTION METHOD | 2019 |
|
RU2781816C1 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| FUSED PROTEIN CONTAINING TGF-BETA RECEPTOR, AND ITS PHARMACEUTICAL USE | 2018 |
|
RU2776204C1 |
